Divamics advances metabolic disease drug discovery with its AI and molecular dynamics platform, enabling breakthroughs like BGM1812, a novel obesity treatment.
 |
| Using AI and molecular dynamics, Divamics empowers partners to discover high-impact drugs like BGM1812, now featured in Journal of Medicinal Chemistry. Image: Divamics |
SUZHOU, China — July 15, 2025:
Divamics, an AI-driven drug discovery innovator based in Suzhou, China, announced a major scientific milestone: its proprietary AI and molecular dynamics (MD) platform enabled the design of BGM1812, a novel dual AMY3R/CTR receptor agonist for obesity treatment. The breakthrough was recently published in the July 2025 issue of the Journal of Medicinal Chemistry, marking a major leap forward in metabolic disease therapeutics.
The BGM1812 compound, developed in collaboration with Brightgene, demonstrated a 50% increase in in vitro potency and significant weight loss and metabolic improvements in preclinical models. These achievements underscore the precision and efficiency made possible by Divamics’ advanced AI platform, which accelerates the drug discovery process by simulating molecular interactions at an atomic level.
Divamics’ technology was pivotal in pinpointing a critical mutation—replacing Ile(Me)24 with Gly(Me)24—to enhance the molecule's anti-aggregation behavior. AI-guided simulations also revealed the formation of a stabilizing "hydrophobic cage" between the drug and receptor. Strategic alpha-carbon methylation, precisely directed by the AI platform, refined the structure of BGM1812 to optimize its therapeutic potential.
“Divamics’ contribution to the development of both BGM1812 and BGM0504 (now in Phase III trials) demonstrates the strength of our platform in tackling complex biological targets,” said Dr. John Zheng, CEO of Divamics. “By reimagining how drug discovery is done, we're enabling our partners to pursue high-value, previously inaccessible therapies.”
With a growing track record of clinical success, Divamics continues to provide its cutting-edge AI and MD capabilities to research teams worldwide, aiming to revolutionize drug discovery in metabolic diseases and beyond.